Poster: Applications- Biologicals/vaccines

Receptor Mediated Disposition PK/PD Model of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations.

Thursday 16 October, 2025

Objectives: To develop a mechanism based pharmacokinetic (PK) and pharmacodynamic (PD) model of human granulocyte-colony stimulating factor (G-CSF), that would…

Read more

Pharmacodynamic Modelling of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Age Distribution in Healthy Subjects

Thursday 16 October, 2025

Objectives: To evaluate the effect of rHu-EPO on reticulocyte production rate and age distribution in healthy subjects. Methods: Four pharmacokinetic…

Read more

Bioequivalence study of a C1-esterase-inhibitor product (Cetor®) with optimised sampling design

Thursday 16 October, 2025

Objectives: Cetor is a concentrate of a highly purified C1-inhibitor concentrate prepared from human fresh frozen plasma, used in the…

Read more

Population modeling of the relationship between TACI Ig exposure and biomarker response in patients with rheumatoid arthritis (RA)

Thursday 16 October, 2025

PDF of posterBackground: TACI‑Ig, a recombinant fusion protein containing the extracellular, ligand-binding portion of the receptor TACI, acts as an…

Read more

Exposure-Response Modeling of the ACR20 Score in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol.

Thursday 16 October, 2025

Objectives: This analysis aimed to describe the exposure-response relationship of certolizumab pegol (CZP) in patients with rheumatoid arthritis, using the…

Read more

Exposure-Response Modeling of the ACR50 Score in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol.

Thursday 16 October, 2025

Objectives: To describe the effect of exposure to certolizumab pegol (CZP) on the ACR20 [1] and ACR50 (American College of…

Read more

Exposure-response analysis of certolizumab pegol in Crohn’s disease population

Thursday 16 October, 2025

Objectives: The objectives of this population analysis were to: 1) characterize the placebo and drug effect of certolizumab pegol (CZP)…

Read more

Application of mechanism-based population PKPD modelling in the rational selection of clinical candidates: an anti-IgE antibody example.

Thursday 16 October, 2025

Objectives: Design, selection and development of clinical candidates should, optimally, incorporate mechanistic PKPD knowledge gained from previous experience with the…

Read more

Relationship Between Serum Concentration of the Interleukin-6 Receptor Inhibitor, Tocilizumab (TCZ), and Disease Activity Score (DAS28) in Patients with Rheumatoid Arthritis

Thursday 16 October, 2025

Objective: To describe the relationship between tocilizumab concentration and the clinical endpoint (DAS28). A secondary objective was to investigate potential…

Read more

Granulocyte Colony Stimulating Factor Pharmacokinetics After Single and Repeated Administration of Several Doses.

Thursday 16 October, 2025

Objectives: Granulocyte Colony Stimulating Factor (G-CSF) pharmacokinetics have a non linear dose and time dependent behavior, with its observed concentration-time…

Read more